Atul Ltd
Atul Ltd. is a diversified and integrated Indian chemical company (a part of Lalbhai Group, Gujarat). The products of the company are used in various Industries and come mainly under two segments, Life Science Chemicals and Performance and Other Chemicals under 9 Businesses. [1]
Since its incorporation, the company has manufactured many products for the first time in India Dyes including Vat Dyes, crop care chemicals, Phosgene, Carbamite, 2,4-D Acid, para Cresol, tissue culture raised date palms. [2]
- Market Cap ₹ 16,417 Cr.
- Current Price ₹ 5,576
- High / Low ₹ 7,198 / 5,525
- Stock P/E 24.6
- Book Value ₹ 2,158
- Dividend Yield 0.54 %
- ROCE 13.2 %
- ROE 10.3 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 2.58 times its book value
- The company has delivered a poor sales growth of 9.64% over past five years.
- Company has a low return on equity of 9.04% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,535 | 2,454 | 2,695 | 3,107 | 3,916 | 3,906 | 3,512 | 4,993 | 5,062 | 4,358 | 5,075 | 5,564 | 6,062 | |
| 2,159 | 2,012 | 2,224 | 2,635 | 3,178 | 3,061 | 2,665 | 4,128 | 4,334 | 3,794 | 4,361 | 4,780 | 5,177 | |
| Operating Profit | 376 | 443 | 470 | 473 | 738 | 845 | 847 | 865 | 728 | 564 | 714 | 784 | 884 |
| OPM % | 15% | 18% | 17% | 15% | 19% | 22% | 24% | 17% | 14% | 13% | 14% | 14% | 15% |
| 15 | 45 | 42 | 38 | 30 | 77 | 103 | 88 | 167 | 132 | 129 | 196 | 188 | |
| Interest | 24 | 26 | 21 | 9 | 4 | 2 | 2 | 3 | 2 | 2 | 6 | 4 | 3 |
| Depreciation | 55 | 62 | 91 | 105 | 112 | 117 | 120 | 146 | 163 | 184 | 213 | 216 | 209 |
| Profit before tax | 312 | 400 | 401 | 397 | 652 | 803 | 828 | 804 | 730 | 510 | 623 | 760 | 859 |
| Tax % | 30% | 31% | 29% | 32% | 34% | 20% | 24% | 24% | 24% | 25% | 27% | 22% | |
| 217 | 274 | 285 | 270 | 429 | 640 | 631 | 608 | 552 | 385 | 456 | 595 | 667 | |
| EPS in Rs | 73.30 | 92.53 | 96.18 | 91.16 | 144.51 | 215.82 | 213.23 | 205.34 | 187.08 | 130.62 | 154.98 | 202.11 | 226.70 |
| Dividend Payout % | 12% | 11% | 10% | 13% | 10% | 13% | 9% | 12% | 17% | 15% | 16% | 15% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 3% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -1% |
| 3 Years: | 2% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -10% |
| 3 Years: | -4% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 29 | 29 | 29 | 29 |
| Reserves | 986 | 1,562 | 1,891 | 2,168 | 2,620 | 3,041 | 3,682 | 4,287 | 4,560 | 5,060 | 5,509 | 6,026 | 6,325 |
| 281 | 302 | 155 | 0 | 0 | 0 | 0 | 73 | 5 | 11 | 8 | 6 | 1 | |
| 465 | 487 | 544 | 722 | 696 | 779 | 876 | 961 | 836 | 905 | 1,005 | 1,234 | 1,357 | |
| Total Liabilities | 1,762 | 2,381 | 2,620 | 2,919 | 3,346 | 3,849 | 4,587 | 5,351 | 5,431 | 6,005 | 6,551 | 7,297 | 7,712 |
| 474 | 713 | 931 | 922 | 921 | 907 | 1,059 | 1,276 | 1,349 | 1,657 | 1,742 | 1,644 | 1,595 | |
| CWIP | 104 | 170 | 37 | 70 | 70 | 235 | 239 | 173 | 356 | 217 | 91 | 81 | 89 |
| Investments | 149 | 449 | 532 | 595 | 926 | 1,330 | 1,551 | 1,551 | 1,128 | 2,460 | 2,829 | 3,444 | 3,648 |
| 1,035 | 1,050 | 1,120 | 1,333 | 1,428 | 1,377 | 1,739 | 2,350 | 2,598 | 1,671 | 1,889 | 2,128 | 2,379 | |
| Total Assets | 1,762 | 2,381 | 2,620 | 2,919 | 3,346 | 3,849 | 4,587 | 5,351 | 5,431 | 6,005 | 6,551 | 7,297 | 7,712 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 317 | 375 | 370 | 325 | 397 | 852 | 677 | 217 | 732 | 624 | 427 | 716 | |
| -196 | -342 | -160 | -87 | -358 | -709 | -603 | -225 | -498 | -483 | -366 | -621 | |
| -123 | -34 | -208 | -224 | -44 | -154 | -64 | 11 | -252 | -133 | -68 | -79 | |
| Net Cash Flow | -3 | -1 | 2 | 15 | -5 | -10 | 10 | 3 | -18 | 8 | -7 | 16 |
| Free Cash Flow | 125 | 18 | 199 | 211 | 276 | 582 | 406 | -80 | 283 | 280 | 238 | 590 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 103% | 108% | 95% | 89% | 87% | 126% | 103% | 47% | 125% | 128% | 80% | 108% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 63 | 62 | 69 | 84 | 71 | 67 | 74 | 77 | 64 | 71 | 74 | 77 |
| Inventory Days | 98 | 111 | 99 | 82 | 76 | 83 | 116 | 98 | 88 | 87 | 91 | 87 |
| Days Payable | 74 | 88 | 88 | 101 | 74 | 93 | 128 | 86 | 72 | 86 | 85 | 98 |
| Cash Conversion Cycle | 88 | 86 | 79 | 65 | 73 | 57 | 62 | 89 | 80 | 71 | 80 | 66 |
| Working Capital Days | 46 | 42 | 64 | 82 | 77 | 58 | 61 | 74 | 82 | 70 | 73 | 66 |
| ROCE % | 26% | 27% | 21% | 19% | 27% | 28% | 24% | 19% | 17% | 11% | 12% | 13% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export share (sales outside India) % |
|
||||||||||
| Number of brands count |
|||||||||||
| Number of countries served count |
|||||||||||
| Number of customers count |
|||||||||||
| Number of products and formulations count |
|||||||||||
| Performance and Other Chemicals segment revenue share % |
|||||||||||
| Captive power plant capacity MW |
|||||||||||
| Number of manufacturing plants in India count |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Communication To The Members Of The Company Regarding Financial Results And Investors'' Presentation For The Second Quarter And Six Months Ended On September 30, 2026
- Board approved Q2/H1 FY2027 unaudited standalone and consolidated results on October 23, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Atul approved ₹90 crore buyback at up to ₹7,500/share; appointed PwC as statutory auditors from 2027.
-
Board Meeting Outcome for Buy-Back Of Share
- Atul approved ₹90 crore buyback at up to ₹7,500/share, announced Q2 FY26 results, and proposed PwC auditor appointment.
-
Results For Period Ended September 30, 2026
- Atul approved ₹90 crore buyback up to ₹7,500/share and appointed PwC as auditor for 2027-32.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Segments[1]
1) Life Science Chemicals (29% in FY26 vs 30% in FY25):
a) Crop Protection - Bulk Actives: [1] [2] The company offers 36 products and 46 formulations across herbicides, insecticides, fungicides, and other crop protection chemicals, serving 224 customers in the Agriculture and Crop Protection Chemicals industries. Key products include 2,4-D, Indoxacarb, and Sulfonylurea herbicides, with a global market share of 13% in 2,4-D and 14% in Indoxacarb as of FY26.